anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND & AIMS: Heterozygous SPINK1 mutations are strong risk factors for chronic pancreatitis in humans, yet heterozygous disruption of mouse Spink1 yielded no pancreatic phenotype. To resolve this contradiction, we used CRISPR/Cas9-mediated genome editing to generate heterozygous Spink1-deleted mice (Spink1-KOhet) in the C57BL/6N strain and studied the effect of this allele in trypsin-independent and trypsin-dependent pancreatitis models.
METHODS: We investigated severity of acute pancreatitis and progression to chronic pancreatitis in Spink1-KOhet mice after transient (10 injections) and prolonged (2 × 8 injections) cerulein hyperstimulation. We crossed Spink1-KOhet mice with T7D23A and T7D22N,K24R mice that carry strongly autoactivating trypsinogen mutants and exhibit spontaneous chronic pancreatitis.
RESULTS: Prolonged but not transient cerulein stimulation resulted in increased intrapancreatic trypsin activity and more severe acute pancreatitis in Spink1-KOhet mice relative to the C57BL/6N control strain. After the acute episode, Spink1-KOhet mice developed progressive disease with chronic pancreatitis-like features, whereas C57BL/6N mice recovered rapidly. Trypsinogen mutant mice carrying the Spink1-KOhet allele exhibited strikingly more severe chronic pancreatitis than the respective parent strains.
CONCLUSIONS: Heterozygous Spink1 deficiency caused more severe acute pancreatitis after prolonged cerulein stimulation and promoted chronic pancreatitis after the cerulein-induced acute episode, and in two strains of trypsinogen mutant mice with spontaneous disease. In contrast, acute pancreatitis induced with limited cerulein hyperstimulation was unaffected by heterozygous Spink1 deletion, in agreement with recent observations that trypsin activity does not mediate pathologic responses in this model. Taken together, the findings strongly support the notion that loss-of-function SPINK1 mutations in humans increase chronic pancreatitis risk in a trypsin-dependent manner.
The present invention relates to a big data application-based network hospital system, comprising a sanitary bureau terminal, a hospital terminal, a doctor terminal and a customer terminal. The sanitary bureau terminal is configured to supervise the hospital terminal. The hospital terminal comprises a central processing unit configured to extract symptom and sign information corresponding to different diseases from an electronic medical record stored by a database, generate a pre-diagnosis information classification table and transmit the pre-diagnosis information classification table to the customer terminal. The customer terminal is connected to the doctor terminal, and comprises a data transmission module, configured to receive the pre-diagnosis information classification table transmitted by the central processing unit, transmit the pre-diagnosis information classification table to a data display module, receive personal symptom and sign information selected, according to the pre-diagnosis information classification table, by a user, and send the personal symptom and sign information to the doctor terminal. The data display module receives the pre-diagnosis information classification table transmitted by the data transmission module, and displays the pre-diagnosis information classification table for user selection. The present invention also provides, according to the above system, a data application method for a database of a big data application-based network hospital system, which is very convenient and quick to use.
CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. Five CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
Cardiovascular toxicity causes adverse drug reactions and may lead to drug removal from the pharmaceutical market. Cancer therapies can induce life-threatening cardiovascular side effects such as arrhythmias, muscle cell death, or vascular dysfunction. New technologies have enabled cardiotoxic compounds to be identified earlier in drug development. Human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs) and vascular endothelial cells (ECs) can screen for drug-induced alterations in cardiovascular cell function and survival. However, most existing hiPSC models for cardiovascular drug toxicity utilize two-dimensional, immature cells grown in static culture. Improved in vitro models to mechanistically interrogate cardiotoxicity would utilize more adult-like, mature hiPSC-derived cells in an integrated system whereby toxic drugs and protective agents can flow between hiPSC-ECs that represent systemic vasculature and hiPSC-CMs that represent heart muscle (myocardium). Such models would be useful for testing the multi-lineage cardiotoxicities of chemotherapeutic drugs such as VEGFR2/PDGFR-inhibiting tyrosine kinase inhibitors (VPTKIs). Here, we develop a multi-lineage, fully-integrated, cardiovascular organ-chip that can enhance hiPSC-EC and hiPSC-CM functional and genetic maturity, model endothelial barrier permeability, and demonstrate long-term functional stability. This microfluidic organ-chip harbors hiPSC-CMs and hiPSC-ECs on separate channels that can be subjected to active fluid flow and rhythmic biomechanical stretch. We demonstrate the utility of this cardiovascular organ-chip as a predictive platform for evaluating multi-lineage VPTKI toxicity. This study may lead to the development of new modalities for the evaluation and prevention of cancer therapy-induced cardiotoxicity.
The periodontal health maintenance will be evaluated by plaque index, periodontal pocket, and gingival inflammation status. Participants will be assigned into two groups after the second dentist visit based on their execution of periodontal health maintenance. Participants whose number of P. gingivalis is unchanged or higher compared to that found at baseline will be considered poor maintenance. Those not having maintained a good dental hygiene will further be randomly assigned to two groups. One group will be given more intense oral health education, while the other one will receive the same education as post therapy. The result of intensive education and a shift in ratio of S. cristatus and P. gingivalis will then be measured for both groups at the third dentist visit (9 months after initial periodontal treatment) and the effectiveness of the intervention will be tested at this stage.
FIELD: organic chemistry. SUBSTANCE: invention relates to the use of 3-substituted para-aminophenol as precursor of oxidative dye for corneous fiber staining, in part, human hair. Product: 3-substituted para-aminophenol of the formula (I)where: Rmeans alkyl, alkenyl, mono- or polyhydroxyalkyl, nitrile, cyanoalkyl, halogenalkyl, aminoalkyl or alkoxyalkyl; Rmeans hydrogen, alkyl or mono- or polyhydroxyalkyl at condition that if Ris hydrogen then Ris not methyl or trifluoromethyl; or indicated 3-substituted para-aminophenol can be prepared as acid additive salt. Invention relates to staining compositions containing compound of the formula (I). Also, invention relates to new 3-substituted para-aminophenols. EFFECT: improved method of synthesis.
Background. Spindle cell/sclerosing rhabdomyosarcoma is a rare neoplasm and has an aggressive clinical course. Because of its rarity, we performed a multi-institutional collaboration to comprehend the overarching clinical, histopathological, and immunohistochemical characteristics of a cohort of spindle cell/sclerosing rhabdomyosarcoma. Materials and Methods. Forty-five patients with spindle cell/sclerosing rhabdomyosarcoma were identified. Demographics, clinical, histopathological, and immunohistochemistry data were reviewed and recorded. Results. The patients' age ranged from 1 to 85 years with a male to female ratio of 1.2:1. There were 15 children/adolescents and 30 adults. Eighteen (40%) tumors were located in the head and neck region. Twenty-four (53%) tumors displayed a bimorphic cellular arrangement with hypercellular areas having short, long, and sweeping fascicular and herringbone pattern, and hypocellular areas with stromal sclerosis and associated hyalinized and/or chondromyxoid matrix. Histomorphological differentials considered were leiomyosarcoma, malignant peripheral nerve sheath tumor, fibrosarcoma, nodular fasciitis, liposarcoma, synovial sarcoma, sarcomatoid carcinoma, solitary fibrous tumor, dermatofibrosarcoma protuberans, and schwannoma. Six tumors exhibited marked stromal sclerosis. The myogenic nature was confirmed by immunohistochemistry. Positivity for at least one skeletal muscle-associated marker (MyoD1 and/or myogenin) was observed. Conclusion. Spindle cell/sclerosing rhabdomyosarcoma diagnosis can be challenging as a number of malignant spindle cell neoplasm mimic this entity. Thus a correct diagnosis requires immunohistochemical work up with a broad panel of antibodies. In view of rarity of this neoplasm, further studies on a large cohort of patients with clinical follow-up data are needed for a better understanding of this tumor.
This group involves patients who will be followed closely for 1 year after all the stones have been removed from the gallbladder. These patients will keep the stent in place for 1 year and at that time the patients will be offered removal of the stent.
PURPOSE:To provide the subject composition for oral cavity, almost free from a bitter taste derived from a quarternary ammonium salt type cationic antibacterial agent, improved in its wild taste, excellent in antibacterial effect and feeling in use, and suitable for prevention and therapy of dental caries, periodontal diseases, oral odor, etc. CONSTITUTION:With (A) 0.005-0.2wt.% quarternary ammonium salt type cationic antibacterial agent, e.g. an alkylpyridinium salt such as benzetonium chloride or a mono-long chain alkyl tri-short chain alkylammonium salt such as cetyltrimethylammonium chloride, (B) 0.005-0.2wt.% tranexamic acid and/or epsilon-aminocaproic acid well known as a component suitable as an additive to a composition in use for oral cavity for giving antiplasmin effect and antiinflammatory effect and (C) 0.0005-0.3wt.% stevia-based sweetening, e.g. stevia extract or stevioside are blended. An excellent bitterness-reducing effect is shown by additive effect of the components (B) and (C). The especially preferable compounding ratios of the each components are respectively within a range of (A)=0.01-0.05wt.%, (B)=0.01-0.1wt.% and (C)=0.001-0.1wt.%.
<P>PROBLEM TO BE SOLVED: To provide an immunological method for treating gastrin-dependent tumors, especially to provide immunogens, immune compositions and methods for treating gastrin-dependent tumors.  <P>SOLUTION: The immunogens comprise a peptide from the CCK-B/gastrin-receptor conjugated to a spacer and to an immune carrier. The immunogens are capable of inducing antibodies in vivo which bind to the CCK-B/gastrin-receptor in tumor cells, thereby preventing growth stimulating peptide hormones from binding to the receptors, and inhibiting tumor cell growth. The immunogens also comprise antibodies against the CCK-B/gastrin-receptor for passive immunization. The immunogens are also usable for the diagnostic methods for detecting gastrin-dependent tumors in vivo or from a tissue biopsy using the antibodies.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The development of neutralizing anti-factor VIII (fVIII) antibodies, fVIII inhibitor, is the most significant complication affecting patients with hemophilia A (HA). Once an inhibitor develops, treatment is less effective and costly. Although inhibitors occur most commonly in those with severe HA, 25% of new inhibitors occur in those with non-severe HA. In patients with non-severe HA, the development of a fVIII inhibitor can change the course of disease from one that is easily managed to one with the potential for spontaneous life-threatening difficult to treat bleeding. Although significant advances have been made in understanding risk factors for fVIII inhibitor development in patients with severe HA, studies that seek to understand the risk for fVIII inhibitor development in those with non-severe disease have been limited to retrospective analyses. In these retrospective analyses, intensive fVIII treatment and surgery have been identified as risk factors for fVIII inhibitor development in non-severe HA. Additionally, receiving fVIII by continuous infusion has been associated with fVIII inhibitor development in non-severe HA in some but not all studies and may be due in part to a more robust proinflammatory response during continuous infusion. Accordingly, the next logical step to evaluate the risk of inhibitor development associated with continuous fVIII infusion is a prospective observational cohort study. Additionally, knowledge of the immune response to fVIII in the surgical setting is essential for identification of patients at high risk for inhibitor development and development of strategies to prevent inhibitor development and is best evaluated in the setting of an prospective cohort study.

This multicenter prospective observational cohort study will enroll a total of 140 subjects at 10 centers who have mild or moderate hemophilia a (fVIII activity 1-40%) who are scheduled to undergo surgery for which at least 5 consecutive days of fVIII replacement therapy is required. The study will gather clinical data and collect blood specimens on 4 occasions over a 3 month period. Outcomes include: inhibitor development, total fVIII usage, bleeding, and markers of T cell activation.
Young adults aged 18-25 with asthma. Vaccination in all cohorts/groups.
Rheumatoid arthritis (RA) is an autoimmune disease that affects joints, causing inflammation, synovitis, and erosion of cartilage and bone. Periplogenin is an active ingredient in the anti-rheumatic and anti-inflammatory herb, cortex periplocae. We conducted a study using a CIA model and an in vitro model of fibroblast-like synoviocytes (FLS) induced by Tumor Necrosis Factor-alpha (TNF-α) stimulation. We evaluated cell activity, proliferation, and migration using the CCK8 test, EDU kit, and transwell assays, as well as network pharmacokinetic analysis of periplogenin targets and RA-related effects. Furthermore, we measured inflammatory factors and matrix metalloproteinases (MMPs) expression using ELISA and qRT-PCR assays. We also evaluated joint destruction using HE and Safranin O-Fast Green Staining and examined the changes in the JAK2/3-STAT3 pathway using western blot. The results indicated that periplogenin can effectively inhibit the secretion of inflammatory factors, suppress the JAK2/3-STAT3 pathway, and impede the proliferation and migration of RA FLS. Thus, periplogenin alleviated the Synovial inflammatory infiltration of RA.
PCT No. PCT/EP94/01422 Sec. 371 Date Jan. 20, 1995 Sec. 102(e) Date Jan. 20, 1995 PCT Filed May 4, 1994 PCT Pub. No. WO95/00104 PCT Pub. Date Jan. 5, 1995The aqueous hair fixing composition is in the form of a highly viscous sprayable gel and contains 0.1 to 50 percent by weight of one or more disaccharides or a mixture of 2 to 37 percent by weight of one or more disaccharides and 63 to 98 percent by weight of one or more oligosaccharides, 0.05 to 30 percent by weight of one or more cationic polymers, and 0.05 to 10 percent by weight of at least one thickener selected from the group consisting of honopolymers of acrylic acid, acrylic acid/acrylamides copolymers and sclerotium gum, The composition of the invention necessarily does hot contain monovalent aliphatic alcohols having 1 to 4 carbon atoms and no inorganic salts of alkali metals or inorganic salts of bivalent or trivalent metals. Either the composition is sprayed with the aid of a mechanical spray device or, alternatively, a gaseous propellant is included in it and the composition and propellant is included under pressure in a dispensing container.
Oxidative stress is a major contributor to brain damage in patients with ischemic stroke. Uric acid (UA) is an endogenous product derived from the metabolism of purins which in man is responsable of the 60% of the total antioxidant capacity of the organism. Recent experimental evidences gathered by our and other research groups have shown that the exogenous administration of UA is neuroprotective both in cortical and subcortical brain areas as the result of its antioxidant properties. In these studies, animals treated with UA disclosed smaller brain infarction after transient focal ischemia, both using the intraluminal model or after the injection of autologous clots. Moreover, our group first described greater neuroprotection in animals pretreated with rtPA (alteplase). Likewise, we have recently shown that the administration of UA was free of serious adverse effects in stroke patients receiving rtPA within 3 hours of stroke onset. Yet, preliminary data suggested that this intervention might translate into clinical benefits at 3 months follow-up. Based on these data, we aim to conduct a phase 3, randomized, double-blind, controlled trial assessing the clinical efficacy of UA administration in acute ischemic stroke patients. Currently, rtPA is the only approved therapy for stroke patients within the first hours of clinical onset, and oxidative stress is thought particularly relevant following ischemia/reperfusion. Based on this ground, we aim to conduct this phase 3 clinical trial in ischemic stroke patients which are currently treated with rtPA within the 4'5 hour window.
Biocompatible wear resistant nanostructured thin film materials are provided for application as coatings in the fabrication of load-bearing implants, for example, orthopedic and dental prosthetics, dental crowns, implants for maxillofacial surgery, artificial limbs, fixtures etc. Requirements to these materials include high hardness, fatigue resistance, wear and corrosion resistance, biocompatibility and absence of toxicity. The multicomponent nanostructured coating (MNC) has high hardness, low elastic modulus, high adhesion to the substrate, low friction coefficient and wear rate, high resistance to long elastic strain to failure and plastic deformation, low surface roughness, negative surface charge in physiological media (4.5<pH<9), bioactive surface, biocompatibility and absence of toxicity. Biocompatible multicomponent nanostructured coatings for load-bearing implants are synthesized on the basis of titanium carbonitride with the addition of elements that improve the mechanical and frictional properties of the coating and provide for its bioactivity, biocompatibility and absence of toxicity. The overall concentrations of the main and additional elements in the coating are in the following relationship: 1 , 2 < ∑ X i ∑ Y j < 20 , where Xi is the overall concentration of the main elements (Ti, C, N) in the coating and Yj is the overall concentration of the additional elements (Ca, Zr, Si, K, Mn, O, P) in the coating. The elemental concentration in the coating is chosen to keep the following component ratios, at. %: Ti:30-50, C:15-40, N:0.5-30, O:5-25, Ca:0-7, Zr:0-20, Si:0-30, P:0-1.5, Mn:0-1.0, K:0-1.0.
BACKGROUND: Nutritional status in pediatric patients undergoing heart transplantation (HT) is frequently a focus of clinical management and requires high resource utilization. Pre-operative nutrition status has been shown to affect post-operative mortality but no studies have been performed to assess how nutritional status may change and the risk of developing nutritional comorbidities long-term in the post-transplant period.
METHODS: A single-center retrospective chart review of patients ≥2 years of age who underwent heart transplantation between 1/1/2005 and 4/30/2020 was performed. Patient data were collected at listing, time of transplant, 1-year, and 3-year follow-up post-transplant. Nutrition status was classified based on body mass index (BMI) percentile in the primary analysis. Alternative nutritional indices, namely the nutrition risk index (NRI), prognostic nutrition index (PNI), and BMI z-score, were utilized in secondary analyses.
RESULTS: Of the 63 patients included, the proportion of patients with overweight/obese status increased from 21% at listing to 41% at 3-year follow-up. No underweight patients at listing became overweight/obese at follow-up. Of patients who were overweight/obese at listing, 88% maintained that status at 3-year follow-up. Overweight/obese status at listing, 1-year, and 3-year post-transplantation were significantly associated with developing metabolic syndrome. In comparison to the alternative nutritional indices, BMI percentile best predicted post-transplant metabolic syndrome.
CONCLUSIONS: The results suggest that pediatric patients who undergo heart transplantation are at risk of developing overweight/obesity and related nutritional sequelae (ie, metabolic syndrome). Improved surveillance and interventions targeted toward overweight/obese HT patients should be investigated to reduce the burden of associated comorbidities.
Once the top dose (i.e., highest tolerated) of Aes-103 has been determined, the size of this group will be expanded with an additional six subjects (Group C) for a total of 12 at that dose, distributed so that six subjects receiving hydroxyurea (HU) and six subjects not receiving HU (for the past 6 months) will receive study drug (five receiving Aes-103 and one receiving placebo in each of the HU and non-HU treated cohorts). This total of 12 subjects includes the initial six subjects who received the highest dose in the study plus six Group C subjects. These subjects will receive a single dose of the top dose of Aes-103 or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second dose of the top dose of Aes-103 and subjects initially randomized to placebo will receive a second dose of placebo; all subjects will be administered a pre-dose, high fat, high protein meal.
Several fixation methods have been described to secure the cochlear implant's receiver/stimulator, but the optimal stabilization technique is still being debated. The aim of this study was to compare the conventional technique with suture fixation to the subperiosteal tight pocket technique in terms of revision cochlear implantation rate. A retrospective review was conducted on the medical records of 649 patients who underwent cochlear implantation. The study participants were divided into different groups regarding the applied surgery technique. The relationship between the fixation technique, revision rates, and the cause of revisions related to techniques was investigated. The overall revision rate was 2.9% (19 out of 649). There were 14 (3.5%) and 5 (2%) revision implantations in the subperiosteal tight pocket and conventional technique groups, respectively. The incidence of device failure was 2.5%, and it constituted the primary cause for revision surgery in both groups. Even though patients who had the subperiosteal tight pocket technique had a much higher rate of device failure, the results indicate that there was no significant difference between the groups, as evidenced by a P-value of .12. The conventional and subperiosteal tight pocket techniques can both be safely preferred with low revision rates in patients undergoing cochlear implantation.